Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1992 1
1993 1
2013 1
2016 1
2017 1
2019 2
2020 1
2021 2
2023 3
2025 2
2026 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

15 results

Results by year

Filters applied: . Clear all
Page 1
B7-33 replicates the vasoprotective functions of human relaxin-2 (serelaxin).
Marshall SA, O'Sullivan K, Ng HH, Bathgate RAD, Parry LJ, Hossain MA, Leo CH. Marshall SA, et al. Eur J Pharmacol. 2017 Jul 15;807:190-197. doi: 10.1016/j.ejphar.2017.05.005. Epub 2017 May 3. Eur J Pharmacol. 2017. PMID: 28478069
This study first compared the rapid vascular effects of an acute bolus injection of B7-33 compared with serelaxin. Male Wistar rats received a tail vein injection of placebo (20mM sodium acetate), B7-33 (13.3mug/kg) or serelaxin (26.6mug/kg). ...Theref …
This study first compared the rapid vascular effects of an acute bolus injection of B7-33 compared with serelaxin. Male Wistar …
B7-33, a Functionally Selective Relaxin Receptor 1 Agonist, Attenuates Myocardial Infarction-Related Adverse Cardiac Remodeling in Mice.
Devarakonda T, Mauro AG, Guzman G, Hovsepian S, Cain C, Das A, Praveen P, Hossain MA, Salloum FN. Devarakonda T, et al. J Am Heart Assoc. 2020 Apr 21;9(8):e015748. doi: 10.1161/JAHA.119.015748. Epub 2020 Apr 16. J Am Heart Assoc. 2020. PMID: 32295457 Free PMC article.
B7-33 (50 and 100 nmol/L) improved cell survival and reduced the expression of GRP78 (glucose regulated protein), an endoplasmic reticulum stress marker. Subsequently, B7-33 (100 nmol/L) reduced tunicamycin (2.5 mug/mL) induced upregulation of GRP78 in …
B7-33 (50 and 100 nmol/L) improved cell survival and reduced the expression of GRP78 (glucose regulated protein), an endoplasm …
The single-chain relaxin mimetic, B7-33, maintains the cardioprotective effects of relaxin and more rapidly reduces left ventricular fibrosis compared to perindopril in an experimental model of cardiomyopathy.
Alam F, Gaspari TA, Kemp-Harper BK, Low E, Aw A, Ferens D, Spizzo I, Jefferis AM, Praveen P, Widdop RE, Bathgate RAD, Hossain MA, Samuel CS. Alam F, et al. Biomed Pharmacother. 2023 Apr;160:114370. doi: 10.1016/j.biopha.2023.114370. Epub 2023 Feb 6. Biomed Pharmacother. 2023. PMID: 36753958 Free article.
Hence, a single chain-derivative of RLX, B7-33, was developed and shown to retain the anti-fibrotic effects of RLX in vitro and in vivo. Here, we determined whether B7-33 could retain the other cardioprotective effects of RLX, and also compared its the …
Hence, a single chain-derivative of RLX, B7-33, was developed and shown to retain the anti-fibrotic effects of RLX in vitro an …
Coatings Releasing the Relaxin Peptide Analogue B7-33 Reduce Fibrotic Encapsulation.
Welch NG, Mukherjee S, Hossain MA, Praveen P, Werkmeister JA, Wade JD, Bathgate RAD, Winkler DA, Thissen H. Welch NG, et al. ACS Appl Mater Interfaces. 2019 Dec 11;11(49):45511-45519. doi: 10.1021/acsami.9b17859. Epub 2019 Dec 2. ACS Appl Mater Interfaces. 2019. PMID: 31713411
In this study, the biodegradable polymer poly(lactic-co-glycolic) acid (PLGA) was used as a coating releasing the relaxin peptide analogue B7-33, which has been demonstrated to reduce organ fibrosis in animal models. While in vitro protein quantification was used to …
In this study, the biodegradable polymer poly(lactic-co-glycolic) acid (PLGA) was used as a coating releasing the relaxin peptide analogue …
Single chain peptide agonists of relaxin receptors.
Praveen P, Kocan M, Valkovic A, Bathgate R, Hossain MA. Praveen P, et al. Mol Cell Endocrinol. 2019 May 1;487:34-39. doi: 10.1016/j.mce.2019.01.008. Epub 2019 Jan 11. Mol Cell Endocrinol. 2019. PMID: 30641102 Review.
This review briefly summarizes the SAR of human relaxin 2 (H2 relaxin) and human relaxin 3 (H3 relaxin) leading to the design and development of single-B-chain only agonists, B7-33 and peptide 5. The physiological functions of these new peptides agonists in cellular …
This review briefly summarizes the SAR of human relaxin 2 (H2 relaxin) and human relaxin 3 (H3 relaxin) leading to the design and developmen …
Dual-functional nanovesicles simultaneously inhibit stromal fibrosis and angiogenesis to suppress cholangiocarcinoma progression.
Zhang L, Duan X, Shi Q, Yao X, Chen Q, Wan J, Wang F, Ni C, Li Y, Wang M, Sheng Y, Zheng W, Liu J, Ji T, Qin Z. Zhang L, et al. J Nanobiotechnology. 2025 Dec 22;23(1):781. doi: 10.1186/s12951-025-03833-w. J Nanobiotechnology. 2025. PMID: 41430305 Free PMC article.
These nanovesicles also retain high levels of integrin alphavbeta3 and specifically carry peptide B7-33 (an inducer of fibroblasts quiescence) modified by the cRGD peptide, thereby developing dual-functional nanovesicles (B7-33-SNPs). The study reveale …
These nanovesicles also retain high levels of integrin alphavbeta3 and specifically carry peptide B7-33 (an inducer of fibrobl …
Further Developments towards a Minimal Potent Derivative of Human Relaxin-2.
Handley TNG, Praveen P, Tailhades J, Wu H, Bathgate RAD, Hossain MA. Handley TNG, et al. Int J Mol Sci. 2023 Aug 11;24(16):12670. doi: 10.3390/ijms241612670. Int J Mol Sci. 2023. PMID: 37628851 Free PMC article.
Native H2 relaxin is a two-chain, three-disulfide-bond-containing peptide, which is unstable in human serum and difficult to synthesize efficiently. In 2016, our group developed B7-33, a single-chain peptide derived from the B-chain of H2 relaxin. B7-33 …
Native H2 relaxin is a two-chain, three-disulfide-bond-containing peptide, which is unstable in human serum and difficult to synthesize effi …
A Lipidated Single-B-Chain Derivative of Relaxin Exhibits Improved In Vitro Serum Stability without Altering Activity.
Praveen P, Wang C, Handley TNG, Wu H, Samuel CS, Bathgate RAD, Hossain MA. Praveen P, et al. Int J Mol Sci. 2023 Apr 1;24(7):6616. doi: 10.3390/ijms24076616. Int J Mol Sci. 2023. PMID: 37047588 Free PMC article.
H2 relaxin has a complex two-chain structure (A and B) and three disulfide bridges. Our laboratory has recently developed B7-33 peptide, a single-chain agonist based on the B-chain of H2 relaxin. However, the peptide B7-33 has a short circulation time …
H2 relaxin has a complex two-chain structure (A and B) and three disulfide bridges. Our laboratory has recently developed B7-33 …
Immune cell uptake of glycinated nanoparticles conjugated to anti-fibrotic peptides enables their prolonged activity and oral administration.
Somanader-Livera DVN, Wei C, Wang C, Li Y, Ferens D, Salimova E, Selomulya C, Hossain MA, Samuel CS, Chakraborty A. Somanader-Livera DVN, et al. J Biomed Sci. 2025 Dec 12;32(1):104. doi: 10.1186/s12929-025-01198-8. J Biomed Sci. 2025. PMID: 41382190 Free PMC article.
The longer-term anti-fibrotic effects of p.o administered SPION-RLX (25 ng/day) or SPION-B7-33 (25 ng/day), a single-chain RLX derivative and relaxin family peptide receptor 1 (RXFP1) agonist were compared to the frontline ACE inhibitor, perindopril (60 ng/day) from …
The longer-term anti-fibrotic effects of p.o administered SPION-RLX (25 ng/day) or SPION-B7-33 (25 ng/day), a single-chain RLX …
Treatment of hepatocellular carcinoma in Child-Pugh B patients.
Piscaglia F, Terzi E, Cucchetti A, Trimarchi C, Granito A, Leoni S, Marinelli S, Pini P, Bolondi L. Piscaglia F, et al. Dig Liver Dis. 2013 Oct;45(10):852-8. doi: 10.1016/j.dld.2013.03.002. Epub 2013 Apr 9. Dig Liver Dis. 2013. PMID: 23582346
RESULTS: Of 86 Child-Pugh B patients, 45 were Barcelona early stage, of which the Child-Pugh scores were 46.7% B7, 33.3% B8, 20.0% B9; 27 patients were intermediate stage (B7 59.3%, B8 37.0% and B9 3.7% respectively), 12 were advanced (41.7% B7, 25.0% B8 and 33.3% B …
RESULTS: Of 86 Child-Pugh B patients, 45 were Barcelona early stage, of which the Child-Pugh scores were 46.7% B7, 33.3% B8, 2 …
15 results